You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

PENICILLIN G POTASSIUM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Penicillin G Potassium patents expire, and when can generic versions of Penicillin G Potassium launch?

Penicillin G Potassium is a drug marketed by Mylan, Purepac Pharm, Acs Dobfar Spa, Apothecon, Consolidated Pharm, Hq Speclt Pharma, Istituto Bio Ita Spa, Lilly, Parke Davis, Pfizer, Sandoz, Watson Labs Inc, Ivax Sub Teva Pharms, Teva, Wyeth Ayerst, and Baxter Hlthcare. and is included in twenty-one NDAs.

The generic ingredient in PENICILLIN G POTASSIUM is penicillin g potassium. There are ninety-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the penicillin g potassium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Penicillin G Potassium

A generic version of PENICILLIN G POTASSIUM was approved as penicillin g potassium by SANDOZ on August 30th, 2002.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PENICILLIN G POTASSIUM?
  • What are the global sales for PENICILLIN G POTASSIUM?
  • What is Average Wholesale Price for PENICILLIN G POTASSIUM?
Summary for PENICILLIN G POTASSIUM
Drug patent expirations by year for PENICILLIN G POTASSIUM
Drug Prices for PENICILLIN G POTASSIUM

See drug prices for PENICILLIN G POTASSIUM

Recent Clinical Trials for PENICILLIN G POTASSIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Alphacait, LLCPhase 2
Haining Health-Coming Biotech Co., Ltd.Phase 2
Phillip Brian SmithPhase 1

See all PENICILLIN G POTASSIUM clinical trials

Pharmacology for PENICILLIN G POTASSIUM

US Patents and Regulatory Information for PENICILLIN G POTASSIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan PENICILLIN G POTASSIUM penicillin g potassium TABLET;ORAL 060781-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Sandoz PENICILLIN G POTASSIUM penicillin g potassium INJECTABLE;INJECTION 065079-003 Aug 30, 2002 AP RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Teva PENICILLIN G POTASSIUM penicillin g potassium TABLET;ORAL 060306-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Purepac Pharm PENICILLIN G POTASSIUM penicillin g potassium TABLET;ORAL 061588-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Teva PENICILLIN G POTASSIUM penicillin g potassium TABLET;ORAL 060306-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Baxter Hlthcare PENICILLIN G POTASSIUM IN PLASTIC CONTAINER penicillin g potassium INJECTABLE;INJECTION 050638-001 Jun 25, 1990 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Parke Davis PENICILLIN G POTASSIUM penicillin g potassium INJECTABLE;INJECTION 062003-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

PENICILLIN G POTASSIUM Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Penicillin G Potassium

Market Overview

The global Penicillin G Potassium market is a significant segment within the broader penicillin drug market, driven by the increasing demand for effective antibiotics to treat bacterial infections.

Market Size and Growth

  • The global Penicillin G Potassium market was valued at approximately USD 1.5 billion in 2023 and is projected to reach around USD 2.5 billion by 2032, indicating a steady growth trajectory[1].

Global Penicillin Drug Market Context

  • The broader penicillin drug market, which includes Penicillin G Potassium, was valued at $8.4 billion in 2022 and is expected to reach $12.1 billion by 2032, growing at a CAGR of 3.7% from 2023 to 2032[4].

Drivers of Growth

Increasing Prevalence of Bacterial Infections

  • The rise in bacterial infections worldwide is a key driver for the growth of the Penicillin G Potassium market. This includes infections caused by susceptible organisms such as Streptococcus pneumoniae, Streptococcus pyogenes, and some gram-negative bacteria like Neisseria meningitidis[4].

Expanding Global Population and Aging Demographics

  • The growing global population, particularly the aging demographics, increases the susceptibility to infections, thereby driving the demand for penicillin drugs[4].

Advancements in Drug Formulation and Delivery

  • Improvements in drug formulation, manufacturing, and delivery systems enhance the accessibility and convenience of penicillin drugs, contributing to market expansion[4].

Healthcare Infrastructure

  • Enhanced healthcare infrastructure, especially in developing regions, improves access to diagnosis and treatment, further boosting the demand for penicillin drugs[4].

Market Segmentation

By Route of Administration

  • The parenteral segment, which includes penicillin injections, dominated the market in terms of revenue in 2022 due to the high adoption rate for treating severe bacterial infections and syphilis. However, the oral segment is expected to grow rapidly due to its cost-effectiveness and ease of administration[4].

By Spectrum of Activity

  • The broad-spectrum penicillin segment, including drugs like amoxicillin, dominated the market in 2022. However, the extended-spectrum penicillin segment is anticipated to grow at a faster rate due to its advantages over natural penicillins and rising awareness about combination medications[4].

By Distribution Channel

  • Drug stores and retail pharmacies hold a significant market share due to the wide availability of penicillin drugs and the presence of knowledgeable pharmacists who can provide counseling on usage and potential side effects[4].

Regional Dynamics

  • North America is a significant market driven by the increasing prevalence of bacterial infections and the burden of antimicrobial resistance. The Asia-Pacific region is also expected to witness notable growth due to increased investments in R&D, a large population base, and growing access to healthcare services[4].

Financial Trajectory

Revenue Projections

  • The Penicillin G Potassium market is expected to grow from USD 1.5 billion in 2023 to USD 2.5 billion by 2032, indicating a robust financial trajectory[1].

Market Share and Competition

  • Major players in the penicillin drug market, including Abbott Laboratories, Alkem Laboratories Ltd., Cipla Ltd, GlaxoSmithKline plc, and others, compete fiercely. The semisynthetic penicillin segment, which includes combination medications, is particularly influential due to its added advantages over natural penicillins[4].

Challenges and Opportunities

Antimicrobial Resistance

  • One of the significant challenges facing the penicillin market is the rise in antimicrobial resistance, which necessitates the development of new and more effective antibiotics[4].

Regulatory and Safety Considerations

  • Penicillin G Potassium must be administered carefully, especially in high doses, due to potential adverse effects such as electrolyte imbalance from the potassium content. This requires strict regulatory oversight and adherence to safety guidelines[2].

Market Expansion Opportunities

  • The growing demand for effective antibiotics, advancements in drug delivery systems, and expanding healthcare infrastructure in developing regions present opportunities for market expansion and innovation[4].

Key Takeaways

  • The Penicillin G Potassium market is driven by the increasing prevalence of bacterial infections and advancements in drug formulation.
  • The parenteral segment currently dominates, but the oral segment is expected to grow rapidly.
  • Regional growth is significant in North America and the Asia-Pacific region.
  • Major players compete in a market influenced by semisynthetic penicillins.
  • Challenges include antimicrobial resistance and regulatory considerations.

FAQs

What is the projected market size of Penicillin G Potassium by 2032?

The global Penicillin G Potassium market is projected to reach around USD 2.5 billion by 2032[1].

Which segment dominates the penicillin drug market by route of administration?

The parenteral segment, which includes penicillin injections, currently dominates the market in terms of revenue[4].

What are the key drivers of the penicillin drug market?

Key drivers include the increasing prevalence of bacterial infections, expanding global population, advancements in drug formulation, and improved healthcare infrastructure[4].

Which region is expected to witness notable growth in the penicillin drug market?

The Asia-Pacific region is anticipated to witness notable growth due to increased investments in R&D, a large population base, and growing access to healthcare services[4].

What are the major challenges facing the penicillin market?

Significant challenges include the rise in antimicrobial resistance and regulatory and safety considerations related to drug administration[2][4].

Sources

  1. Dataintelo: Global Penicillin G Potassium Market Research Report 2032.
  2. FDA: Penicillin G Potassium Injection, USP.
  3. Ken Research: Global Penicillin G Potassium Industry Report.
  4. Allied Market Research: Penicillin Drug Market Size, Share & Growth Report, 2032.
  5. WICZ: Penicillin G Potassium Market By Application Report 2032.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.